Patients ( n = @ ) with refractory breast cancer that expressed gpNMB in @ % of epithelial or stromal cells by central immunohistochemistry were stratified by gpNMB expression ( tumor , low stromal intensity , high stromal intensity ) and were randomly assigned @:@ to glembatumumab vedotin ( n = @ ) or investigator 's choice ( IC ) chemotherapy ( n = @ ) .